ES2601892T3 - Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes - Google Patents
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes Download PDFInfo
- Publication number
- ES2601892T3 ES2601892T3 ES12774372.2T ES12774372T ES2601892T3 ES 2601892 T3 ES2601892 T3 ES 2601892T3 ES 12774372 T ES12774372 T ES 12774372T ES 2601892 T3 ES2601892 T3 ES 2601892T3
- Authority
- ES
- Spain
- Prior art keywords
- pentapolymer
- treatment
- random
- autoimmune diseases
- vehicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 229920005684 linear copolymer Polymers 0.000 abstract 1
- 235000018977 lysine Nutrition 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 235000008729 phenylalanine Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 235000002374 tyrosine Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un pentapolímero o una sal del mismo, que es un copolímero lineal de alanina, ácido glutámico, lisina, tirosina y fenilalanina.
Description
suspensión blanca homogénea, capaz de ser extraída e inyectada a través de una aguja adecuada.
Formación de vehículos:
5 Vehículo 1: solución salina, 0,9% de NaCL en agua estéril Vehículo 2: agua para inyección (WFI)
Reactivos:
MOG 35-55: (GL BiochemCo. Ltd; Shanghái, P.R. China). MOG 35-55. El MOG 35-55 se disuelve en solución salina a una concentración de 2 mg/ml.
Adyuvante Completo de Freund (CFA) (Cat: F5881; Sigma-Aldrich; St. Louis, MO, USA).Se añade la cepa Mycobacterium tuberculosis H37RA matada por calor (Cat: 231141; Difco; Detroit, MI, USA) al adyuvante completo 15 de Freund a una concentración final de 4 mg/ml.
Toxina de Bordetella pertussis (PTX): (Cat: P7208; Sigma-Aldrich; St. Louis, MO, USA).
Usando un homogeneizador de alta velocidad, la solución MOG anterior se emulsifica con volumen igual del CFA modificado en hielo para 30.000 rpm durante 1,5 horas.
Animales:
Ratones C57BL/6, hembra, 7 -9 semanas, 17 -20 g.
25 Adaptación: no menos de 7 días. Ambiente: ambiente Libre de Patógenos Específicos (SPF) Temperatura ambiente: 20 -26C Humedad relativa ambiente: 40 -70% Ciclo de luz: luz fluorescente durante 12 horas de luz (08:00 -20:00) y 12 horas de oscuridad. Alojamiento de animales: 3-4 ratones/caja por grupo de tratamiento Alimentación: acceso libre a comida (irradiada, Shanghai SLAC Laboratory Animal Co. Ltd., China). Agua: acceso libre a agua (agua del grifo filtrada por Mol Ultrapure Water System).
Asignación a grupos de tratamiento: 35 Los animales se asignaron a los grupos de tratamiento por aleatorización en software Biobook para lograr peso medio de grupo similar, que proporciona control del error sistemático.
Tabla 1 -Grupo y régimen de dosificación
45
55
- Grupo Artículo de Prueba N Vía Conc. Dosificción Régimen Dosis en (días)
- mg/ml ml/ratones mg/ratone s
- 1 PPb 10 s.c. 10 0.2 2 q.d. DO-9
- 2 GAb 10 i.m. 25 0.2 5 q.d. D0, 1, 14, 15, 28,29
- 3 GAb 10 i.m. 25 0.2 5 q.d. D0, 14, 28
- 4 GAb 10 i.m. 25 0.2 5 q.d. D0, 7, 14,21, 28
- 5 GA-depósitob 10 i.m. 312 0.2 62.5* q.d. D0, 1, 14, 15, 28,29
- 6 GA-depósitob 10 i.m. 312 0.2 62.5* q.d. D0, 14, 28
- 7 GA-depósitob 10 i.m. 312 0.2 62.5* q.d. D0, 7, 14,21, 28
- 8 GAb 10 s.c. 10 0.2 2 q.d. DO-9
- 9 Veha 10 s.c. N/A 0.2 N / q.d. DO-9
- a: Vehículo en solución salina b: Vehículo es WFI * contenido de Ga es 80 mg/g de producto formulado "GA-depósito", es decir 5 mg/ratones/día de GA.
11
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477610P | 2011-04-21 | 2011-04-21 | |
| US201161477610P | 2011-04-21 | ||
| PCT/IL2012/050138 WO2012143924A1 (en) | 2011-04-21 | 2012-04-16 | Random pentapolymer for treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2601892T3 true ES2601892T3 (es) | 2017-02-16 |
Family
ID=47041117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12774372.2T Active ES2601892T3 (es) | 2011-04-21 | 2012-04-16 | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9200114B2 (es) |
| EP (1) | EP2699317B1 (es) |
| ES (1) | ES2601892T3 (es) |
| WO (1) | WO2012143924A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| EP3027174B1 (en) * | 2013-07-29 | 2019-07-24 | Aizant Drug Research Solutions Private Limited | Pharmaceutical compositions of fingolimod |
| AU2016361579B2 (en) | 2015-11-25 | 2022-08-04 | Incept, Llc | Shape changing drug delivery devices and methods |
| EP3478300B1 (en) * | 2016-06-30 | 2022-08-24 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| WO2018042423A1 (en) | 2016-08-28 | 2018-03-08 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| IL269893B2 (en) | 2017-05-15 | 2023-10-01 | Stem Cell Medicine Ltd | Treatment of multiple sclerosis with adipose-derived stem cells |
| EP3624815A4 (en) | 2017-05-15 | 2021-01-20 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5578442A (en) | 1992-03-23 | 1996-11-26 | Vivorx, Inc. | Graft copolymers of polycationic species and water-soluble polymers, and use therefor |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5858964A (en) | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| IT1276690B1 (it) | 1995-06-09 | 1997-11-03 | Ira Srl | Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES |
| US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| HK1054507B (zh) | 2000-01-20 | 2008-10-31 | 耶达研究及发展有限公司 | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 |
| DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
| US6835711B2 (en) | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| JP4426286B2 (ja) | 2001-07-10 | 2010-03-03 | テバ ファーマシューティカル インダストリーズ リミティド | ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム |
| IL161121A0 (en) * | 2001-10-03 | 2004-08-31 | Harvard College | Copolymers for suppression of autoimmune diseases, and methods of use |
| WO2003048207A2 (en) | 2001-11-28 | 2003-06-12 | Immunomedics, Inc. | Anti-dota antibody |
| US7351686B2 (en) | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| WO2004060265A2 (en) | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| US20050142205A1 (en) | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| US8075919B2 (en) | 2003-07-18 | 2011-12-13 | Baxter International Inc. | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| US20060276390A1 (en) | 2003-07-31 | 2006-12-07 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| JP2007509981A (ja) | 2003-10-31 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物デリバリー用ナノ粒子 |
| CA2546077C (en) | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| KR101242486B1 (ko) | 2004-01-12 | 2013-03-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 장기 전달을 위한 제형 및 그의 이용 방법 |
| RU2006134701A (ru) * | 2004-03-01 | 2008-04-10 | Пептиммьюн | Способы и композиции для лечения аутоиммунных заболеваний |
| US7576051B2 (en) | 2004-03-11 | 2009-08-18 | Sanyo Chemical Industries, Ltd. | Wound dressing for accelerating epidermal regeneration |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| DK1799703T3 (da) | 2004-09-09 | 2010-04-19 | Teva Pharma | Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid |
| ES2541780T3 (es) | 2004-11-29 | 2015-07-24 | Yeda Research And Development Co., Ltd. | Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1 |
| AU2006211101A1 (en) | 2005-02-02 | 2006-08-10 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| WO2007127977A2 (en) | 2006-04-28 | 2007-11-08 | Momenta Pharmaceuticals, Inc. | Methods of evaluating peptide mixtures |
| JP5412280B2 (ja) | 2006-06-28 | 2014-02-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 加齢性黄斑変性症の治療法 |
| WO2008075365A1 (en) | 2006-12-20 | 2008-06-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for treatment of age related degeneration of the retina |
| CA2693697C (en) | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| WO2009063459A2 (en) | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| CA2732228A1 (en) | 2008-07-25 | 2010-01-28 | The Johns Hopkins University | Methods and compositions for treating and preventing autoimmune diseases |
| EP2398499B1 (en) | 2009-02-18 | 2017-09-06 | Eyeon Particle Sciences LLC | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
| WO2011080733A1 (en) | 2010-01-04 | 2011-07-07 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
-
2012
- 2012-04-16 ES ES12774372.2T patent/ES2601892T3/es active Active
- 2012-04-16 WO PCT/IL2012/050138 patent/WO2012143924A1/en not_active Ceased
- 2012-04-16 EP EP12774372.2A patent/EP2699317B1/en active Active
-
2013
- 2013-02-11 US US13/764,460 patent/US9200114B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9200114B2 (en) | 2015-12-01 |
| WO2012143924A1 (en) | 2012-10-26 |
| EP2699317B1 (en) | 2016-08-10 |
| US20130156725A1 (en) | 2013-06-20 |
| EP2699317A1 (en) | 2014-02-26 |
| EP2699317A4 (en) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kathayat et al. | Avian pathogenic Escherichia coli (APEC): an overview of virulence and pathogenesis factors, zoonotic potential, and control strategies | |
| Barrett et al. | Vaccines for biodefense and emerging and neglected diseases | |
| Haiko et al. | The role of the bacterial flagellum in adhesion and virulence | |
| Hernández‐Cabanyero et al. | Phylogeny and life cycle of the zoonotic pathogen Vibrio vulnificus | |
| Wiles et al. | Origins and virulence mechanisms of uropathogenic Escherichia coli | |
| Hwang et al. | Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon‐like peptide 1 in diet‐induced obesity | |
| CN108478790B (zh) | Bt脂肽作为用于肥胖和相关疾病的治疗剂的用途 | |
| Romstad et al. | Comparision of a serological potency assay for furunculosis vaccines (Aeromonas salmonicida subsp. salmonicida) to intraperitoneal challenge in Atlantic salmon (Salmo salar L.) | |
| Rzeznitzeck et al. | The effect of Campylobacter jejuni and Campylobacter coli colonization on the gut morphology, functional integrity, and microbiota composition of female turkeys | |
| Xu et al. | Emerging risks in food: probiotic enterococci pose a threat to public health through the food chain | |
| Cortés et al. | In vivo efficacy of purified quillaja saponin extracts in protecting against piscirickettsia salmonis infections in Atlantic Salmon (Salmo salar) | |
| Abdel-Wahab et al. | Effects of humic acid as feed additive in improvement of nonspecific immune response and disease resistance in common carp (Cyprinus carpio) | |
| Abubakar et al. | An evaluation of foot–and–mouth disease outbreak in relation to vaccination in a herd of cattle and buffaloes | |
| Subhasinghe et al. | Induction of trained immunity in broiler chickens following delivery of oligodeoxynucleotide containing CpG motifs to protect against Escherichia coli septicemia | |
| Maina et al. | Staphylococcal enterotoxin A has potent superantigenic and emetic activities but not diarrheagenic activity | |
| Ross et al. | Rise of informal slums and the next global pandemic | |
| ES2659538T3 (es) | Preparaciones de factor de transferencia y métodos asociados | |
| JP6712760B2 (ja) | サルモネラワクチン | |
| RU2358758C1 (ru) | Способ профилактики колибактериоза и сальмонеллеза поросят | |
| US7910620B2 (en) | Uses of neuraminidase inhibitors in infectious diseases | |
| RU2523389C1 (ru) | Способ получения гипериммунной сыворотки против анаэробной энтеротоксемии и эшерихиозной диареи телят | |
| Popoff | Advances in Clostridial Neurotoxins: Passage of the Intestinal Barrier and Targeting of Specific Neuronal Cells | |
| RU2395278C1 (ru) | Способ получения комплексного препарата для профилактики и лечения патологий обмена веществ и нарушений функций иммунной системы животных | |
| Robinett | The effect of Salmonella autogenous vaccination on serotype surveillance, recovery, and phenotypic characteristics | |
| MA et al. | Pathogenicity of Vibrio fluvialis Isolated from Seacoast |